TY - JOUR
T1 - Isoeugenol suppression of inducible nitric oxide synthase expression is mediated by down-regulation of NF-κB, ERK1/2, and p38 kinase
AU - Choi, Chun Yeon
AU - Park, Kyung Ran
AU - Lee, Jung Hee
AU - Jeon, Young Jin
AU - Liu, Kwang Hyeon
AU - Oh, Sangtaek
AU - Kim, Dong Eun
AU - Yea, Sung Su
PY - 2007/12/8
Y1 - 2007/12/8
N2 - Isoeugenol, which is a naturally occurring o-methoxyphenol in a variety of foods and essential oils, is known to have anti-inflammatory effects, although the mechanism is not clear. In the present study, we investigated the effect of isoeugenol on NF-κB signaling leading to inducible nitric oxide synthase (iNOS) expression in RAW 264.7 murine macrophages stimulated with lipopolysaccharide (LPS). Isoeugenol markedly inhibited nitric oxide (NO) production in dose- and time-dependent manners. The decrease in NO production was found to correlate with a decrease in iNOS expression, as determined by Western blot analysis and real-time RT-PCR. To characterize further the inhibitory mechanisms of isoeugenol at the transcriptional level, we examined the DNA-binding and transcriptional activities of NF-κB. Isoeugenol inhibited NF-κB-dependent transcriptional activity and DNA-binding activity by decreasing the nuclear translocation of p65, which is a component of NF-κB. In addition, isoeugenol blocked signaling upstream of NF-κB activation, such as degradation of I-κBα and the phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) and p38 mitogen-activated protein kinase (MAPK), in LPS-stimulated RAW 264.7 cells. The isoeugenol analogues eugenol and allylbenzene also inhibited LPS-induced NF-κB signaling and iNOS expression, albeit with less potency than isoeugenol. These results suggest that isoeugenol and its analogues inhibit NO production and iNOS expression in LPS-stimulated RAW 264.7 cells, and that these effects are mediated, at least in part, by blocking the phosphorylation of ERK1/2 and p38 kinase, degradation of I-κBα, and activation of NF-κB.
AB - Isoeugenol, which is a naturally occurring o-methoxyphenol in a variety of foods and essential oils, is known to have anti-inflammatory effects, although the mechanism is not clear. In the present study, we investigated the effect of isoeugenol on NF-κB signaling leading to inducible nitric oxide synthase (iNOS) expression in RAW 264.7 murine macrophages stimulated with lipopolysaccharide (LPS). Isoeugenol markedly inhibited nitric oxide (NO) production in dose- and time-dependent manners. The decrease in NO production was found to correlate with a decrease in iNOS expression, as determined by Western blot analysis and real-time RT-PCR. To characterize further the inhibitory mechanisms of isoeugenol at the transcriptional level, we examined the DNA-binding and transcriptional activities of NF-κB. Isoeugenol inhibited NF-κB-dependent transcriptional activity and DNA-binding activity by decreasing the nuclear translocation of p65, which is a component of NF-κB. In addition, isoeugenol blocked signaling upstream of NF-κB activation, such as degradation of I-κBα and the phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) and p38 mitogen-activated protein kinase (MAPK), in LPS-stimulated RAW 264.7 cells. The isoeugenol analogues eugenol and allylbenzene also inhibited LPS-induced NF-κB signaling and iNOS expression, albeit with less potency than isoeugenol. These results suggest that isoeugenol and its analogues inhibit NO production and iNOS expression in LPS-stimulated RAW 264.7 cells, and that these effects are mediated, at least in part, by blocking the phosphorylation of ERK1/2 and p38 kinase, degradation of I-κBα, and activation of NF-κB.
KW - Eugenol
KW - Extracellular signal-regulated kinase 1/2
KW - Inducible nitric oxide synthase
KW - Inhibitory κBα
KW - Isoeugenol
KW - Nuclear factor-κB
KW - p38 kinase
UR - http://www.scopus.com/inward/record.url?scp=35348900146&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2007.07.034
DO - 10.1016/j.ejphar.2007.07.034
M3 - Article
C2 - 17698059
AN - SCOPUS:35348900146
SN - 0014-2999
VL - 576
SP - 151
EP - 159
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 1-3
ER -